Review: PET imaging with macro- and middle-sized molecular probes

Hidefumi Mukai; Yasuyoshi Watanabe

doi:10.1016/j.nucmedbio.2020.06.007

Review: PET imaging with macro- and middle-sized molecular probes

Nucl Med Biol. 2021 Jan:92:156-170. doi: 10.1016/j.nucmedbio.2020.06.007. Epub 2020 Jun 24.

Authors

Hidefumi Mukai¹, Yasuyoshi Watanabe²

Affiliations

¹ Laboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan. Electronic address: hmukai@riken.jp.
² Laboratory for Pathophysiological and Health Science, RIKEN Center for Biosystems Dynamics Research, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan. Electronic address: yywata@riken.jp.

PMID: 32660789
DOI: 10.1016/j.nucmedbio.2020.06.007

Abstract

Recent progress in radiolabeling of macro- and middle-sized molecular probes has been extending possibilities to use PET molecular imaging for dynamic application to drug development and therapeutic evaluation. Theranostics concept also accelerated the use of macro- and middle-sized molecular probes for sharpening the contrast of proper target recognition even the cellular types/subtypes and proper selection of the patients who should be treated by the same molecules recognition. Here, brief summary of the present status of immuno-PET, and then further development of advanced technologies related to immuno-PET, peptidic PET probes, and nucleic acids PET probes are described.

Keywords: Antibodies PET probes; Chelator development; Drug delivery system (DDS); Immuno-PET; Nucleic acids PET probes; Peptidic PET probes; Pharmacokinetics; Radiolabeling.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Humans
Molecular Probes / chemistry*
Positron-Emission Tomography / methods*

Substances

Molecular Probes